Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-09-27 02:01 UTC

BIOMED PULSE

Sunday, September 27, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus (Ebola) outbreak in the Democratic Republic of the Congo is now the largest Ebola outbreak ever recorded in that country, having expanded to 61 health zones across six provinces as of mid-September 2026, with sustained cross-border transmission into Uganda. Mood: Grave on the outbreak front, with incremental but real progress in longevity science and a freshly expanded Listeria alert demanding your refrigerator check today.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS (EBOLA) - DRC AND UGANDA: RECORD-BREAKING OUTBREAK

  • As of September 25, 2026, the Bundibugyo virus disease (BVD) outbreak in the DRC has expanded to two additional health zones, including Bulu in the newly affected province of Sud Ubangi, on the northwest border of the country, raising the total to 61 affected health zones across six provinces: Bas-Uele, Haut-Uele, Ituri, North Kivu, South Kivu, and Tshopo. [1]
  • WHO DON-618 characterizes this as the largest Ebola outbreak ever reported in the DRC, driven by intense, sustained transmission and ongoing cross-border spread into Uganda. [1]
  • As of July 15, 2026 (the most recent confirmed case-count snapshot in the DON series), a cumulative 2,124 confirmed cases and 828 deaths had been reported from the DRC alone; case counts have continued rising since. [2]
  • CDC mobilized its international Ebola response on May 17, 2026, and enhanced airport screening was established at Washington-Dulles and Atlanta Hartsfield-Jackson international airports to screen travelers arriving from affected areas. [3][4][5]

LISTERIA - PREPARED MEALS OUTBREAK EXPANDING

  • CDC expanded its Listeria monocytogenes outbreak alert on September 26, 2026 to include additional prepared meal products; 3 new illnesses and 1 additional death have been added to the case count. [6][7]
  • Consumers are urged to check refrigerators and freezers immediately for all recalled prepared meals linked to this outbreak strain and discard any found. [8]

DRUG-RESISTANT BACTERIA: SHARP RISE FLAGGED

  • A CDC report published September 23, 2026 found a dramatic increase in dangerous drug-resistant bacteria circulating in the United States, a signal that antimicrobial resistance (AMR) pressure is intensifying. [9]
  • Separately, CDC data released September 24, 2026 show U.S. newborn (congenital) syphilis cases increased for the 12th consecutive year in 2024, underscoring continued gaps in STI prevention and prenatal screening. [10]

ANIMAL RABIES: RISING HUMAN EXPOSURE RISK

  • CDC issued a statement on September 10, 2026 flagging a notable increase in recent animal rabies activity and associated human exposures in the United States; residents in affected areas are advised to avoid contact with wildlife and ensure pet vaccinations are current.

HANTAVIRUS (ANDES VIRUS) - M/V HONDIUS CRUISE SHIP: WINDING DOWN BUT MONITORED

  • The fifth and most recent WHO DON (July 2, 2026) on the Andes hantavirus (ANDV) cluster linked to cruise ship M/V Hondius confirmed additional cases since the prior report; the outbreak originated May 2, 2026 among passengers and crew aboard the vessel.
  • CDC provided its own hantavirus response updates through late June 2026, noting the overall public risk remains low.

CANCER MORTALITY: A RARE BRIGHT SPOT

  • An Annual Report to the Nation published September 22, 2026 shows progress against lung cancer is driving down overall U.S. cancer mortality rates, reflecting the continued impact of reduced smoking prevalence and improved treatments.

🧬 LONGEVITY & AGING

SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE (SASP): BETTER TOOLS TO STUDY IT

  • Koutsoukos et al. (Methods in Molecular Biology) describe validated multiplex assay methods to characterize the SASP in both primary skin cells and iPSC-derived skin cells, giving researchers better tools to quantify the cocktail of inflammatory signals that senescent cells emit and that accelerate tissue aging.

IONIZING RADIATION AND CELLULAR SENESCENCE IN HAIR FOLLICLES

  • Jia et al. (Genes and Disease) found that ionizing radiation induces senescence in dermal papilla cells - the key cells that signal hair follicle growth - by inhibiting the FOXM1-KIF20A molecular pathway, offering a mechanistic target to counter radiation-related hair loss and possibly broader radiation-induced tissue aging.

MOLECULAR HYDROGEN AS A RADIOPROTECTIVE AGENT

  • Ichikawa et al. (Medical Gas Research, September 2026) propose molecular hydrogen as a potential guardian against environmental radiation damage, reviewing evidence that H2 scavenges reactive oxygen species generated by ionizing radiation, a mechanism relevant to both cancer therapy side effects and occupational radiation exposure.

mRNA LIPID NANOPARTICLES TO FIX AGE-RELATED BONE DEFECTS

  • Cheng et al. (Bioactive Materials, August 2026) describe a dual-targeting mRNA lipid nanoparticle system that restores ABCA1-dependent cholesterol homeostasis in bone tissue, demonstrating repair of age-related bone defects in preclinical models - combining the mRNA delivery technology of COVID vaccines with a bone-aging target.

FRAILTY AND INFLUENZA VACCINES: HIGH-DOSE WINS WHERE IT MATTERS MOST

  • Verschoor and Kuchel (Lancet Healthy Longevity, August 2026) highlight what they call the "frailty-influenza paradox": frail older adults face the highest risk from influenza yet derive the greatest relative benefit from high-dose influenza vaccines compared to standard-dose formulations.
  • A prespecified analysis of the Danish DANFLU-2 randomised trial (Lancet Healthy Longevity) confirms that high-dose influenza vaccine was more effective than standard-dose at preventing hospitalisation, with the magnitude of benefit tracking frailty risk level.

DEPRESCRIBING IN OLDER ADULTS: TRIAL DESIGN DEBATE

  • Two linked commentaries in Lancet Healthy Longevity (August 2026) by Hwang, Boockvar, and Steinman, and separately by Van der Linden, argue that deprescribing trials - studies of safely stopping medications in older patients - need a rationale-first framework to choose the right study design before enrolling participants, a debate with direct implications for polypharmacy management in aging populations.

HIP FRACTURE SURGERY IN OLDER PATIENTS: SPINAL BEATS GENERAL ANAESTHESIA

  • A multicentre randomised clinical trial published in Lancet Healthy Longevity (August 2026) by Kowark et al. from Germany found that spinal anaesthesia was associated with fewer serious complications compared to general anaesthesia in older patients undergoing hip fracture surgery - a common and high-mortality procedure in the elderly.

NARCICLASINE IDENTIFIED AS DUAL VCAM-1/ICAM-1 INHIBITOR FOR ATHEROSCLEROSIS

  • Wang et al. (Genes and Disease) used single-cell sequencing to guide the discovery that narciclasine, a plant-derived alkaloid, inhibits both VCAM-1 and ICAM-1 - two adhesion molecules central to atherosclerotic plaque formation - suggesting a potential new approach to managing age-related cardiovascular disease.

OSTEOPOROTIC BONE REGENERATION VIA SMART NANOCOMPOSITE HYDROGEL

  • Yin et al. (Bioactive Materials, August 2026) report a quercetin-derived carbon dot and M2 macrophage-derived migrasome-functionalized microenvironment-responsive nanocomposite hydrogel that promotes regeneration of osteoporotic bone defects in preclinical models, combining anti-inflammatory quercetin chemistry with immune cell-derived signals.

UROLITHIN A AND GLUCOSE METABOLISM IN ADULTS 55 AND OLDER

  • A randomized triple-masked controlled clinical trial (NCT06274749, ClinicalTrials.gov) is actively evaluating whether Urolithin A (UA) supplementation improves glucose metabolism and insulin sensitivity in healthy adults aged 55 and older, addressing the well-established age-related decline in pancreatic beta-cell insulin output.

💊 NEW CURES & APPROVALS

INLURIYO (IMLUNESTRANT TOSYLATE) - ELI LILLY AND CO: NEW BREAST CANCER INDICATION

  • Eli Lilly and Co received a supplemental approval (SUPPL AP) for Inluriyo (imlunestrant tosylate, NDA218881), an oral selective estrogen receptor degrader (SERD) targeting ER-positive breast cancer, adding to the company's oncology portfolio.

VERZENIO (ABEMACICLIB) - ELI LILLY AND CO: EXPANDED INDICATION

  • Eli Lilly and Co received a supplemental approval for Verzenio (abemaciclib, NDA208716), a CDK4/6 inhibitor used in hormone receptor-positive, HER2-negative breast cancer, reflecting continued label expansion for this class.

NUBEQA (DAROLUTAMIDE) - BAYER HEALTHCARE: SUPPLEMENTAL APPROVAL

  • Bayer Healthcare received a supplemental approval for Nubeqa (darolutamide, NDA212099), an androgen receptor inhibitor for prostate cancer treatment.

SCEMBLIX (ASCIMINIB HCl) - NOVARTIS: SUPPLEMENTAL APPROVAL

  • Novartis received a supplemental approval for Scemblix (asciminib hydrochloride, NDA215358), a STAMP inhibitor targeting the BCR-ABL1 kinase in chronic myeloid leukemia (CML), which works differently from prior-generation TKIs by binding outside the ATP pocket.

WINREVAIR (SOTATERCEPT-CSRK) - MERCK SHARP AND DOHME: SUPPLEMENTAL APPROVAL

  • Merck Sharp and Dohme received a supplemental approval for Winrevair (sotatercept-csrk, BLA761363), an activin signaling inhibitor for pulmonary arterial hypertension (PAH), continuing label refinements for this first-in-class agent.

SOHONOS (PALOVAROTENE) - IPSEN: SUPPLEMENTAL APPROVAL

  • Ipsen received a supplemental approval for Sohonos (palovarotene, NDA215559), a retinoic acid receptor gamma agonist indicated for fibrodysplasia ossificans progressiva (FOP), a rare and severe disorder of abnormal bone formation.

AQNEURSA (LEVACETYLLEUCINE) - INTRABIO: SUPPLEMENTAL APPROVAL

  • IntraBio received a supplemental approval for Aqneursa (levacetylleucine, NDA219132), indicated for neurological manifestations of Niemann-Pick disease type C, a rare lysosomal storage disorder.

DEFLAZACORT - HIKMA: GENERIC APPROVAL

  • Hikma received an original ANDA approval (ANDA220524) for deflazacort, a corticosteroid with established use in Duchenne muscular dystrophy.

LANREOTIDE ACETATE - AMNEAL: GENERIC APPROVAL

  • Amneal received an original ANDA approval (ANDA218217) for lanreotide acetate, a somatostatin analogue used in acromegaly and neuroendocrine tumors.

🧪 CLINICAL TRIALS

TRONTINEMAB IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE (NCT07170150)

  • A clinical trial registered September 25, 2026 is assessing the efficacy and safety of trontinemab - an anti-amyloid antibody designed for enhanced brain penetration - in participants with early symptomatic Alzheimer's disease, ranging from mild cognitive impairment to mild dementia with confirmed AD pathology.

UROLITHIN A FOR GLUCOSE METABOLISM IN ADULTS 55 PLUS (NCT06274749)

  • A randomized triple-masked controlled trial is evaluating Urolithin A (UA) supplementation's effects on insulin secretion and glucose control in healthy adults 55 years and older, targeting the mitophagy pathway as a mechanism to counter metabolic aging.

ENHANCING PHYSICAL RESERVE IN FRAIL OLDER ADULTS (NCT07513701)

  • A trial registered September 25, 2026 is assessing combined aerobic and resistance training to build physical reserve in older adults with physical frailty, with primary endpoints including preservation of both cognitive and physical function over time.

VIRTUAL LIFE STORY CLUB FOR LONELINESS AND APATHY IN OLDER ADULTS (NCT06919094)

  • A trial is testing a virtual group reminiscence therapy intervention (Life Story Club) to reduce loneliness and apathy in community-dwelling older adults, a non-pharmacological approach targeting two of the most prevalent and health-damaging conditions of aging.

VELOCITY-LOSS RESISTANCE TRAINING IN PARKINSON'S DISEASE (NCT07840508)

  • A new trial registered September 25, 2026 will compare 10% versus 30% velocity-loss resistance training thresholds on muscle strength, power, and daily performance in older adults with Parkinson's disease, a population in urgent need of evidence-based exercise prescriptions.

BPL-1357 UNIVERSAL INFLUENZA VACCINE CANDIDATE (NCT07215858)

  • A human challenge trial is testing BPL-1357 - a broad-spectrum influenza vaccine candidate - against H1N1 influenza virus challenge, aiming to demonstrate protection beyond seasonal flu strains in preparation for pandemic influenza scenarios.

📢 PUBLIC HEALTH

LISTERIA OUTBREAK - CHECK YOUR FRIDGE NOW

  • CDC expanded the ongoing Listeria monocytogenes outbreak linked to prepared meals on September 26, 2026, adding more products to the recall list; do not eat any recalled prepared meals and discard immediately - new illnesses are still being reported despite prior recalls. [6][7]

CONGENITAL SYPHILIS: 12TH CONSECUTIVE YEAR OF INCREASES

  • CDC data released September 24, 2026 confirm U.S. newborn syphilis cases rose for the 12th year in a row through 2024, underscoring the need for universal prenatal STI screening and treatment. [10]

AMR SIGNAL: DRUG-RESISTANT BACTERIA RISING SHARPLY

  • A CDC report from September 23, 2026 documents a dramatic increase in dangerous drug-resistant bacteria, a reminder that antimicrobial stewardship in hospitals and communities remains an urgent priority. [9]

ANIMAL RABIES EXPOSURES INCREASING IN THE U.S.

  • CDC flagged on September 10, 2026 that animal rabies activity and associated human exposures have increased recently; post-exposure prophylaxis (PEP) remains highly effective if started promptly after a bite or scratch from a potentially rabid animal.

CANCER PROGRESS: LUNG CANCER DECLINING

  • The 2026 Annual Report to the Nation (September 22, 2026) shows falling U.S. cancer death rates overall, with lung cancer reductions as a primary driver - largely attributed to decades of tobacco control and advances in early detection and targeted therapies.

NOTE: BIOMED PULSE is informational only and is not medical advice. Consult a licensed healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  3. CDC Mobilizes International Response Following Ebola Disease O… — CDC Newsroom
  4. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  5. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  6. CDC expands Listeria outbreak to include more prepared meals — CDC Newsroom
  7. Listeria Outbreak to include more Prepared Foods — CDC Newsroom
  8. CDC continues to note illnesses despite product recalls and as… — CDC Newsroom
  9. CDC Report Finds Sharp Rise in Dangerous Drug-Resistant Bacteria — CDC Newsroom
  10. CDC Reports Latest National Data on Syphilis in Newborns and S… — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260927-02-v88 · 2026-09-27 02:01 UTC · pulse.uzylab.com

Read next